Literature DB >> 3697994

Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione.

Y Yoda, M Nakazawa, T Abe, Z Kawakami.   

Abstract

The effect of reduced glutathione (GSH) on acute myocardial toxicity due to doxorubicin (DXR) was investigated. At 20 mg/kg i.p. DXR was 100% lethal to BALB/c X DBA/2 F1 mice. At 500 or 1000 mg/kg i.p. GSH significantly decreased the lethality (P less than 0.01). Electron micrographs of the myocardium from DXR-treated mice showed narrowing of myofibrils, edematous cytoplasm, and mitochondrial swelling which were detectable at day 2, was strongest at day 14, but had disappeared by day 56. Light microscopic examination revealed that intercellular spaces between myocardial cells were widened at day 56, indicating shrinking of myocardial cells. These changes were significantly decreased by treatment with GSH (500 mg/kg i.p.). Treatment with DXR (14 mg/kg) significantly decreased myocardial non-protein sulfhydryl content (P less than 0.02) and administration of GSH (500 mg/kg) prevented the drop of non-protein sulfhydryl levels due to DXR treatment. Thus it was considered that administration of exogenous GSH contributes to prevention of the acute myocardial toxicity of DXR by increasing extracellular GSH levels and intracellular GSH synthesis, which detoxifies DXR-oxygen metabolites. The administration of GSH did not interfere with the antineoplastic effect of DXR against L1210 mouse leukemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3697994

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

Authors:  Bo-Yu Shen; Chong Chen; Yang-Fan Xu; Jia-Jia Shen; Hui-Min Guo; Hao-Feng Li; Xi-Nuo Li; Dian Kang; Yu-Hao Shao; Zhang-Pei Zhu; Xiao-Xi Yin; Lin Xie; Guang-Ji Wang; Yan Liang
Journal:  Acta Pharmacol Sin       Date:  2018-09-14       Impact factor: 6.150

2.  Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.

Authors:  Yukitaka Shizukuda; Satoaki Matoba; Omar Y Mian; Tammy Nguyen; Paul M Hwang
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

Review 3.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

4.  Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy.

Authors:  N Iliskovic; B B Hasinoff; K L Malisza; T Li; I Danelisen; P K Singal
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

5.  Obesity, longevity, quality of life: alteration by dietary 2-mercaptoethanol.

Authors:  Robert E Click
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

Review 6.  The role of antioxidants in the era of cardio‑oncology.

Authors:  Duncan T Vincent; Yasmine F Ibrahim; Michael Graham Espey; Yuichiro J Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2013-12       Impact factor: 3.333

7.  Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol.

Authors:  R Buhl; C Vogelmeier; M Critenden; R C Hubbard; R F Hoyt; E M Wilson; A M Cantin; R G Crystal
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

8.  Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment.

Authors:  K J Holroyd; R Buhl; Z Borok; J H Roum; A D Bokser; G J Grimes; D Czerski; A M Cantin; R G Crystal
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

9.  A mouse model for juvenile doxorubicin-induced cardiac dysfunction.

Authors:  Wuqiang Zhu; Weinian Shou; R Mark Payne; Randall Caldwell; Loren J Field
Journal:  Pediatr Res       Date:  2008-11       Impact factor: 3.756

10.  Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine.

Authors:  M M al-Harbi; N M al-Gharably; O A al-Shabanah; A M al-Bekairi; A M Osman; H N Tawfik
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.